PMC:7091888 / 4689-4885 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"193","span":{"begin":33,"end":41},"obj":"Species"},{"id":"194","span":{"begin":170,"end":178},"obj":"Species"},{"id":"198","span":{"begin":100,"end":132},"obj":"Disease"}],"attributes":[{"id":"A193","pred":"tao:has_database_id","subj":"193","obj":"Tax:694009"},{"id":"A194","pred":"tao:has_database_id","subj":"194","obj":"Tax:694009"},{"id":"A198","pred":"tao:has_database_id","subj":"198","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"g cells. We have also shown that SARS-CoV RBD-specific polyclonal antibodies could cross-neutralize SARS-CoV-2 pseudovirus infection, suggesting the potential to develop SARS-CoV RBD-based vaccine"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T19","span":{"begin":2,"end":7},"obj":"Body_part"}],"attributes":[{"id":"A19","pred":"fma_id","subj":"T19","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"g cells. We have also shown that SARS-CoV RBD-specific polyclonal antibodies could cross-neutralize SARS-CoV-2 pseudovirus infection, suggesting the potential to develop SARS-CoV RBD-based vaccine"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T82","span":{"begin":33,"end":41},"obj":"Disease"},{"id":"T83","span":{"begin":33,"end":37},"obj":"Disease"},{"id":"T84","span":{"begin":100,"end":108},"obj":"Disease"},{"id":"T85","span":{"begin":100,"end":104},"obj":"Disease"},{"id":"T86","span":{"begin":123,"end":132},"obj":"Disease"},{"id":"T87","span":{"begin":170,"end":178},"obj":"Disease"},{"id":"T88","span":{"begin":170,"end":174},"obj":"Disease"}],"attributes":[{"id":"A82","pred":"mondo_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A83","pred":"mondo_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A84","pred":"mondo_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A85","pred":"mondo_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A86","pred":"mondo_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A87","pred":"mondo_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A88","pred":"mondo_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"g cells. We have also shown that SARS-CoV RBD-specific polyclonal antibodies could cross-neutralize SARS-CoV-2 pseudovirus infection, suggesting the potential to develop SARS-CoV RBD-based vaccine"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T42","span":{"begin":2,"end":7},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"g cells. We have also shown that SARS-CoV RBD-specific polyclonal antibodies could cross-neutralize SARS-CoV-2 pseudovirus infection, suggesting the potential to develop SARS-CoV RBD-based vaccine"}